


GSK-690693

## Chemical Properties

CAS No. : 937174-76-0  
 Formula: C<sub>21</sub>H<sub>27</sub>N<sub>7</sub>O<sub>3</sub>  
 Molecular Weight: 425.48  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	GSK-690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC <sub>50</sub> of 2 nM/13 nM/9 nM, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.
Targets(IC <sub>50</sub> )	Akt,AMPK,Autophagy,PKC,Serine Protease
In vitro	GSK690693 exhibits high specificity for Akt isoforms compared to most other kinase families, though it shows lower selectivity for AGC kinase family members, including PKA, PrkX, and PKC isozymes, with IC <sub>50</sub> values of 24 nM, 5 nM, and 2-21 nM, respectively. It also effectively inhibits AMPK and DAPK3 from the CAMK family and PAK4, 5, and 6 from the STE family, with IC <sub>50</sub> values of 50 nM, 81 nM, 10 nM, 52 nM, and 6 nM, respectively. GSK690693 prevents GSK3β phosphorylation in tumor cells, with IC <sub>50</sub> values ranging 43-150 nM, and promotes dose-dependent nuclear accumulation of FOXO3A. It strongly suppresses the proliferation of various cancer cell lines, including T47D, ZR-75-1, BT474, HCC1954, MDA-MB-453, and LNCaP, with IC <sub>50</sub> values of 72 nM, 79 nM, 86 nM, 119 nM, 975 nM, and 147 nM, respectively, and induces apoptosis in LNCaP and BT474 cells at concentrations above 100 nM. [1] In alignment with AKT's role in cell survival, GSK690693 triggers apoptosis in sensitive ALL cell lines. [2]
In vivo	Administering a single dose of GSK690693 effectively inhibits GSK3β phosphorylation in human breast carcinoma (BT474) xenografts, with its impact varying by dose and time. It also leads to a decrease in phosphorylation of Akt substrates, including PRAS40 and FKHR/FKHRL1. Additionally, GSK690693 causes a temporary spike in blood glucose levels, which normalize within 8 to 10 hours post-administration. This compound not only significantly reduces phosphorylated Akt substrates in vivo but also powerfully restricts growth in various human carcinoma xenografts such as SKOV-3 ovarian, LNCaP prostate, and BT474 and HCC-1954 breast, achieving up to 58% to 75% growth inhibition at a 30 mg/kg/day dosage. Its effectiveness is consistent across different Akt activation mechanisms and notably excels in delaying tumor progression in Lck-MyrAkt2 mice, which express an always-active, membrane-bound form of Akt.
Kinase Assay	In vitro kinase assays: His-tagged full-length Akt1, 2, or 3 are expressed and purified from baculovirus. Activation is carried out with purified PDK1 to phosphorylate Thr308 and purified MK2 to phosphorylate Ser473. To more accurately measure time-dependent inhibition of Akt, activated Akt enzymes are incubated with GSK690693 at various concentrations at room temperature for 30 minutes before the reaction is initiated with the addition of substrate. Final reaction contains 5 nM to 15 nM Akt1, 2, and 3 enzymes;

## A DRUG SCREENING EXPERT

Kinase Assay	2 $\mu$ M ATP; 0.15 $\mu$ Ci/ $\mu$ L[ $\gamma$ -33P]ATP; 1 $\mu$ M Peptide (Biotin-aminohexanoicacid-ARKR-ERAYSFGHHA-amide); 10 mM MgCl <sub>2</sub> ; 25 mM MOPS (pH 7.5); 1 mM DTT; 1 mM CHAPS; and 50 mM KCl. The reactions are incubated at room temperature for 45 minutes, followed by termination with Leadseeker beads in PBS containing EDTA (final concentration, 2 mg/mL beads and 75 mM EDTA). The plates are then sealed, the beads are allowed to settle for at least 5 hours, and product formation is quantitated using a Viewlux Imager.
Cell Research	Cells are plated at densities that allow untreated cells to grow logarithmically during the course of a 3-day assay. Briefly, cells are plated in 96- or 384-well plates and incubated overnight. Cells are then treated with GSK690693 (ranging from 30 $\mu$ M-1.5 nM) and incubated for 72 hours. Cell proliferation is measured using the CellTiter Glo reagent. Data are analyzed using the XLFit curve-fitting tool for Microsoft Excel. IC <sub>50</sub> values are obtained by fitting data to Eq. 2.(Only for Reference)
Animal Research	Animal Models: Female CD1 Swiss Nude mice injected with LNCaP, SKOV-3, or PANC1 cells, and C.B-17 SCID mice with HCC1954, MDA-MB-453, or BT474 cells Formulation: Formulated in either 4% DMSO/40% hydroxypropyl- $\beta$ -cyclodextrin in water (pH 6.0) or 5% dextrose (pH 4.0) Dosages: ~30 mg/kg/day Administration: Administered via i.p.

### Solubility Information

Solubility	DMF: soluble, DMSO: 18.33 mg/mL (43.08 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.7 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3503 mL	11.7514 mL	23.5029 mL
5 mM	0.4701 mL	2.3503 mL	4.7006 mL
10 mM	0.235 mL	1.1751 mL	2.3503 mL
50 mM	0.047 mL	0.235 mL	0.4701 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Rhodes N, et al. Cancer Res, 2008, 68(7), 2366-2374.

Liu H, Liu Y, Wang H, et al. Geometric Constraints Regulate Energy Metabolism and Cellular Contractility in Vascular Smooth Muscle Cells by Coordinating Mitochondrial DNA Methylation. Advanced Science. 2022: 2203995.

Yin J, Chen J, Hong J H, et al. 4EBP1-mediated SLC7A11 protein synthesis restrains ferroptosis triggered by MEK inhibitors in advanced ovarian cancer. JCI insight. 2024

Levy DS, et al. Blood, 2009, 113(8), 1723-1729.

Altomare DA, et al. Clin Cancer Res, 2010, 16(2), 486-496.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286

E\_mail: info@targetmol.com

Address: 34 Washington Street, Wellesley Hills, MA 02481